New York, NY (PRWEB) April 17, 2014
Allergan, the leader in the medical aesthetics category, announced that the company had received approval from the U.S. Food and Drug Administration to market JUVÉDERM VOLUMA™ XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. JUVÉDERM VOLUMA™ XC helps create a more youthful appearance to the face and with long-lasting results up to two years with ideal treatment.
Allergan conducted a clinical trial in the United States and Canada for submission to the FDA. The trial was designed to assess the safety and effectiveness of JUVÉDERM VOLUMA™ XC as a non-surgical option for patients desiring volume in the cheek area to correct age-related volume loss. The trial determined that JUVÉDERM VOLUMA™ XC was an effective treatment compared to the control group, which did not receive treatment.
"Overtime, one of the first signs of aging is volume loss in the cheek area, causing the cheeks to flatten out and the skin to sag," said Dr. Julie Russak, Assistant Clinical Professor, Mount Sinai and Founder of Russak Dermatology Clinic. What sets JUVÉDERM VOLUMA™ XC apart from other fillers on the market is Allergan's newly developed VYCROSS™ technology, an advanced manufacturing process that results in a smooth gel that with a lifting capacity to correct volume loss in the cheek area and lift the drooping skin in the jowl area. "My patients that are looking to restore cheek volume loss and lift sagging skin that resulted from the lost cheek volume can now treat two concerns with one product," says Dr. Russak. "Juvederm Voluma XC has only been readily available since February, 2014," says Dr. Russak. "I couldn't wait to start using the product and offer it to my patients, especially since it's been a great success in Europe for so long. I am very impressed with the lifting capabilities of this ultra thick filler."
The JUVÉDERM VOLUMA™ formulation without lidocaine was first introduced in Europe in 2005. JUVÉDERM VOLUMA™ with lidocaine was first introduced outside the U.S. in 2009. As of August 31, 2013, JUVÉDERM VOLUMA™ with lidocaine (branded as JUVÉDERM VOLUMA™ XC in the U.S.) is distributed in 72 countries, including markets in Europe, Latin America, Middle East, Asia Pacific, and Canada. The JUVÉDERM® family of products, including JUVÉDERM® Ultra and Ultra Plus, are marketed and sold in 85 countries outside the United States.
For more information about Julie E. Russak, M.D., and Russak Dermatology Clinic, visit russakdermatology.com or follow her practice on Facebook and Twitter (@RussakDerm). To interview or make an appointment with Dr. Russak, contact Juliet Cavallaro at juliet(at)russakdermatolgy(dot)com or (646) 873-7546.
About Julie E. Russak, M.D.
Dr. Russak is a board-certified dermatologist, a Fellow of the American Academy of Dermatology, and a member of the American Society of Dermatologic Surgery. She graduated with honors from New York University School of Medicine and completed her dermatology residency at the Dartmouth Hitchcock Medical Center, where she served as chief resident. She completed an Oncology Melanoma Fellowship with world-renowned melanoma expert Darrell Rigel, M.D., and is the recipient of the Marianne Salzberg Award in Dermatology and the Jonas E. Salk Scholar Award. In addition to having a thriving practice, she is an assistant clinical professor at Mount Sinai Hospital, where she teaches dermatology residents and medical students.
Russak Dermatology Clinic is located in the GALLERIA building at 115 East 57th Street. Designed by the internationally acclaimed Antonio Tadrissi of Prototype Design Lab, known for its innovative architecture style, the stylish boutique space features amazing views of midtown Manhattan and sleek and spacious treatment rooms equipped with the latest technology and amenities. Flat screens in every room and WiFi accessibility throughout the clinic ensure a comfortable and relaxing patient experience.
The clinic offers treatments for a wide variety of medical conditions of the skin, hair, and nails, including skin cancer, acne, rosacea, psoriasis, hair loss, and varicose veins. Within the medical division, Dr. Russak is one of the few doctors in New York City to be trained in the use of MelaFind®, the first FDA-approved non-invasive and painless medical device to detect melanoma in its earliest stages. She also provides dermatological skin-cancer surgery on the premises.